← Shelf·Cyclic melanocortin agonist·XI.
PT-141.
A cyclic 7-amino-acid peptide melanocortin-receptor agonist developed by Palatin Technologies from the α-MSH template. The compound corresponds to the INN bremelanotide, which is FDA-approved as a prescription drug for a single specific clinical indication.
α-MSH is a hormone your pituitary and skin cells produce, engaging the melanocortin receptor family (MC1R–MC5R). PT-141 is a synthetic analog designed for stability and receptor selectivity distinct from native α-MSH.
The most-searched sexual-function peptide on the internet. The receptor pharmacology and Palatin's clinical trials are heavily published. Consumer marketing runs miles past what the FDA label authorizes anyone to say about it.
Straight talk
Straight talk: the melanocortin-receptor pharmacology and Palatin's clinical trial data are legitimate and published. Whether the research-grade PT-141 in a given vial IS the same molecule as the FDA-approved drug of the same INN is exactly what a third-party COA is for. Buy on documentation, not on brand adjacency. Documented adverse effects include flushing, nausea, and — meaningfully — persistent blood-pressure elevation.
What the research studies
The literature, not a summary of it.
Palatin's clinical program (Kingsberg, Simon, Clayton and colleagues) is the core clinical record. Upstream melanocortin-receptor pharmacology sits with Cone, Gantz, and the receptor-cloning-era literature. Journals: Obstet Gynecol, J Sex Med, Peptides, J Endocrinol. Read the research yourself:
Recommended vendor · Amino Club
≥ 99% by HPLC on the current lot — ILS Laboratories (ISO/IEC 17025).
$19.49 during Fall Sale (was $29.99)
35% off applied automatically at checkout when you land through this link.
Related on the shelf